Development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma

Chen, Yidan; Liang, Zhong-Yuan; Cen, Yanyan; Zhang, He; Han, Ming‐Lun; Tian, Yun-Qiao; Zhang, Jie; Li, Shujun; Da-sheng, Yang

doi:10.2147/dddt.s86075

Cited by 14 publications

(5 citation statements)

References 24 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lyophilization can be used to improve the physical and chemical stabilities of nanoparticle formulations. Moreover, lyophilized SLNs can be easily formulated into other dosage forms such as capsules [ 15 , 16 ], tablets [ 17 , 18 ], and films [ 19 ]. The formulations obtained show that beeswax–theobroma oil (1:1) can be used to prepare SLNs containing hydrophilic and hydrophobic drugs.…”

Section: Resultsmentioning

confidence: 99%

Lyophilized Drug-Loaded Solid Lipid Nanoparticles Formulated with Beeswax and Theobroma Oil

Amekyeh

Billa

2021

Molecules

View full text Add to dashboard Cite

Solid lipid nanoparticles (SLNs) have the potential to enhance the systemic availability of an active pharmaceutical ingredient (API) or reduce its toxicity through uptake of the SLNs from the gastrointestinal tract or controlled release of the API, respectively. In both aspects, the responses of the lipid matrix to external challenges is crucial. Here, we evaluate the effects of lyophilization on key responses of 1:1 beeswax–theobroma oil matrix SLNs using three model drugs: amphotericin B (AMB), paracetamol (PAR), and sulfasalazine (SSZ). Fresh SLNs were stable with sizes ranging between 206.5–236.9 nm. Lyophilization and storage for 24 months (4–8 °C) caused a 1.6- and 1.5-fold increase in size, respectively, in all three SLNs. Zeta potential was >60 mV in fresh, stored, and lyophilized SLNs, indicating good colloidal stability. Drug release was not significantly affected by lyophilization up to 8 h. Drug release percentages at end time were 11.8 ± 0.4, 65.9 ± 0.04, and 31.4 ± 1.95% from fresh AMB-SLNs, PAR-SLNs, and SSZ-SLNs, respectively, and 11.4 ± 0.4, 76.04 ± 0.21, and 31.6 ± 0.33% from lyophilized SLNs, respectively. Thus, rate of release is dependent on API solubility (AMB < SSZ < PAR). Drug release from each matrix followed the Higuchi model and was not affected by lyophilization. The above SLNs show potential for use in delivering hydrophilic and lipophilic drugs.

show abstract

Section: Resultsmentioning

confidence: 99%

Lyophilized Drug-Loaded Solid Lipid Nanoparticles Formulated with Beeswax and Theobroma Oil

Amekyeh

Billa

2021

Molecules

View full text Add to dashboard Cite

show abstract

“…62 Due to the inherent benefits associated with nanocrystals, the proposition is to devise ODTs containing vortioxetine, aiming to augment its aqueous solubility, elevate the dissolution properties, and enhance release kinetics, surpassing the dissolution performance of unprocessed drug (60%) within an equivalent time frame. 14 Chen et al 63 further proposed that ODTs containing fast disintegrating nanoparticles may present a superior option for young children. These ODTs were constructed at various compositions of microcrystalline cellulose, lactose, croscarmellose sodium for achieving optimal PDS-enhanced solubility, in vitro drug release (98.50% in 30 min), and integration time (15 s).…”

Section: Orally Disintegratingmentioning

confidence: 99%

Tabletized Nanomedicine: From the Current Scenario to Developing Future Medicine

Tiwari,

Kolli,

Chauhan

et al. 2024

ACS Nano

View full text Add to dashboard Cite

The limitations of conventional therapeutic treatments prevailed in the development of nanotechnology-based medical formulations, termed nanomedicine. Nanomedicine is an advanced medicine that often consists of therapeutic agent(s) embedded in biodegradable or biocompatible nanomaterial-based formulations. Among nanomedicine approaches, tablet (oral) nanomedicine is still under development. In tabletized nanomedicine, the dynamic interplay between nanoformulations and the intricate milieu of the gastrointestinal tract simulates a pivotal role, particularly accentuating the influence exerted upon the luminal, mucosal, and epithelial cells. In this work, we document the perspectives and opportunities of nanoformulations toward the development of tabletized nanomedicine. This review also unveils the notion of integrating nanomedicine within a tablet formulation, which facilitates the controlled release of drugs, biomolecules, and agent(s) from the formulation to achieve a better therapeutic response. Finally, an attempt was made to explore current trends in nanomedicine technology such as bacteriophage, probiotic, and oligonucleotide tabletized nanomedicine and the combination of nanomedicine with imaging agents, i.e., nanotheranostics.

show abstract

“…Firstly, it increases the viscosity of the tablet matrix, creating a physical barrier that hampers the diffusion of drug molecules, leading to slower or restricted drug release. [25] Secondly, CCS can form a gel-like network at higher concentrations when exposed to water or saliva, further impeding drug diffusion and dissolution. [26] Thirdly, increased CCS concentration contributes to greater tablet hardness, which can hinder disintegration and dissolution, resulting in decreased drug release.…”

Section: Dissolution Of Vrz Compressed Tabletsmentioning

confidence: 99%

Formulation and Development of Voriconazole Tablets Containing Solid Dispersion With Enhanced Solubility, Dissolution and Bioavailability

Velhal,

Salunkhe

2024

Int. J. Pharm. Sci. Drug Res.

View full text Add to dashboard Cite

This research work enhances the solubility, dissolution and bioavailability of Voriconazole which belongs to BCS II class. Carboxymethyl tamarind gum was synthesized by using carboxymethylation of tamarind gum. Solid dispersion of Voriconazole was developed by kneading method followed by immediate release tablets. Solid dispersion characterised for solubility and instrumental analysis. Tablets were evaluated for dissolution study. Solid dispersions were confirmed by presence of distinctive peaks at 1745.58 cm-1 (C=O) and 1402 cm-1 (-COO-), using Infrared spectroscopy. The weight loss of 3.91% and 54.42 % at 100°C and in the rage of 235°C-425°C respectively was observed. 13C nuclear magnetic resonance spectrum of carboxymethyl tamarind gum displayed three distinct peaks of C1, -OH, and CH2O- group. X-ray diffraction analysis confirmed that ccarboxymethyl tamarind gum exhibits an amorphous structure. Soild dispersion of Voriconazole were developed using the kneading method, incorporating carboxymethyl tamarind gum. Compared to traditional methods, Solid dispersion formulated with carboxymethyl tamarind gum demonstrated a significant increase in solubility enhancement, ranging from 68.12 to 74.37-fold. Notably, the SD5 formulation exhibited complete release from the solid dispersion within 120 minutes. In rat models, Voriconazole levels in the bloodstream were markedly elevated with the administration of solid dispersion. Furthermore, dissolution profiles of all formulation batches showed considerable improvement. These findings shed light on effective strategies for enhancing the dissolution and bioavailability of poorly soluble drugs, thus contributing to the advancement of drug delivery systems.

show abstract

Development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma

Cited by 14 publications

References 24 publications

Lyophilized Drug-Loaded Solid Lipid Nanoparticles Formulated with Beeswax and Theobroma Oil

Lyophilized Drug-Loaded Solid Lipid Nanoparticles Formulated with Beeswax and Theobroma Oil

Tabletized Nanomedicine: From the Current Scenario to Developing Future Medicine

Formulation and Development of Voriconazole Tablets Containing Solid Dispersion With Enhanced Solubility, Dissolution and Bioavailability

Contact Info

Product

Resources

About